Navigation Links
Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
Date:8/1/2008

EXTON, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it will release its earnings results for its fourth quarter and fiscal year ended June 30, 2008 at 7:00 A.M. Eastern Time on Thursday, August 21, 2008.

Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Thursday, August 21, 2008 at 9:00 A.M. Eastern Time.

To participate in the teleconference call, dial 612-332-0345. The teleconference call will also be available for replay starting Thursday, August 21, 2008 at 11:00 A.M. Eastern Time through Thursday, August 28, 2008 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 956292.

Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com. To listen to the live teleconference call, please go to the http://www.kenseynash.com website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com website and may be accessed following the teleconference.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also developed and commercialized a series of innovative endovascular products and recently announced the sale of this product line to Spectranetics, Inc. In conjunction with the sale transaction, the Company will continue to manufacture and develop these products for Spectranetics for a period of time. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
2. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
3. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
4. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
5. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
6. Kensey Nash Reports Third Quarter Record Revenue and Sales
7. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
10. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
11. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... IL (PRWEB) , ... February 28, 2017 , ... Today, ... ten years of saving lives by empowering young women to live proactively at a ... 1 in 75 will develop ovarian cancer. Prevention and early detection can save lives-but ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... America for the scientific development, healthcare training and clinical application of medical infrared ... Session on September 16-17 in Greenville, SC at the Bon Secours St. Francis ...
(Date:2/28/2017)... CA (PRWEB) , ... February 28, 2017 , ... ... Health Coach Institute (HCI) announced a new partnership through which HCI students, ... their coaching curriculum and practices. The partnership also enables the HCI community to ...
(Date:2/28/2017)... ... February 28, 2017 , ... In 2014, Harvard researchers published a report ... from prostate cancer, the researchers found that men who had undergone a vasectomy were ... prostate cancer. Although the increased risks are small, they seem to be contradicted by ...
(Date:2/28/2017)... ... ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud to announce the ... pm PST. For more than six decades, LVSCC has provided the Las Vegas community ... been renovated to provide medical and cosmetic dermatological products and services. Patients at the ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Calif. , Feb. 27, 2017  Titan ... therapeutics for the treatment of select chronic diseases ... today announced that the U.S. Food & Drug ... the ropinirole implant Investigational New Drug Application (IND) ... of the clinical study pending submission of the ...
(Date:2/28/2017)... and SAN FRANCISCO , February 27, 2017 ... Se D BioMedical ... of biotechnology assets   LOI contemplates capital infusion ... for building shareholder value   Amarantus names four new appointees ... Amarantus   SeD Biomedical Inc. (SeD ...
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
Breaking Medicine Technology: